Pictor Holdings announced that it has closed a $7.5 million bridge round of growth capital. The financing was supported by existing investors and brings Pictor’s total capital raised to approximately $30 million.
Pictor is a global targeted proteomic platform company headquartered in Carlsbad, California.
The company will use the funding to expand commercial partnerships, scale platform development and manufacturing capabilities, and support translational studies across key human and animal health markets.
The financing builds on Pictor’s commercial momentum following its first year at its U.S. headquarters.
During that period, Pictor launched seven commercial products, secured four strategic partnerships, and expanded its leadership team.
Recent executive appointments include Terry Kelly, PhD, as Chief Operating Officer and Tim Shannon as Chief Financial Officer.
Pictor’s targeted proteomic platform includes PictArray, PictImager, and Pictorial software.
The platform enables laboratories to analyze up to 20 protein targets from a single sample in under two hours.
The system is designed to reduce cost and workflow complexity while delivering lower per-sample economics across pharmaceutical, reference laboratory, and animal health markets.
The bridge round will support continued expansion of Pictor’s partner network and advancement of large-scale translational studies across priority markets.
Pictor expects to enter licensing stages with multiple partners within the next 12 to 18 months.
The company is also evaluating a U.S.-based Series A financing to support its next phase of growth.
Pictor plans to use future growth capital to further expand commercial operations, platform development, and strategic partnerships.
Pictor has laboratory and commercial operations in New Zealand, Australia, and India.
The company develops multi-analyte proteomic assay solutions for human and animal health research environments.
Pictor’s intellectual property portfolio includes 16 patents, five pending patents, and seven registered trademarks.
KEY QUOTES:
“Proteomic assays should not be limited to the largest, most specialized settings. Pictor’s platform is designed to make protein insights more accessible, practical, and economical, so more partners can use them to improve health and wellness across people and animals. By helping labs generate more information from a single sample with fewer consumables, we also see an opportunity to support One Health and sustainability goals as adoption scales.”
Jamie Platt, PhD, CEO and Co-Founder of Pictor Holdings
“The continued support of our existing investors reflects confidence in both the platform and the commercial model we’ve built around it. This capital positions Pictor to accelerate partnerships and scale operations as we advance toward our Series A.”
Tim Shannon, CPA, Chief Financial Officer of Pictor Holdings
